Transgene announced encouraging interim results in three Phase II clinical trials of its MVA-Muc1-IL2 cancer vaccine candidate in lung, prostate and kidney cancers.
The three ongoing trials are designed to assess MVA-Muc1-IL2 in different treatment modalities: in combination with standard chemotherapy (lung cancer); at different dosing schedules (prostate cancer); and in combination with standard immunotherapy (kidney cancer).
Transgene reported the following accomplishments in its MVA-Muc1-IL2 Phase II clinical programmes:
Enrollment is completed for the Phase II trials in non-small cell lung cancer and metastatic renal cell carcinoma. Good tolerance and safety have been observed at all doses and dosing schedules tested.
An encouraging rate of tumour responses was observed in a preliminary analysis of the lung cancer trial of MVA-Muc1-IL2 in combination with chemotherapy.
A highly significant decrease in PSA progression rate in the prostate cancer trial indicates biological activity.
"We are delighted with the progress shown by our Phase II interim data," stated Jean-Francois Carmier, CEO of Transgene. "It confirms the potential of our cancer vaccine candidate as an innovative and safe therapeutic approach for the treatment of cancer at different stages of the disease."